Nomogram Based on microRNA Signature Contributes to Improve Survival Prediction of Clear Cell Renal Cell Carcinoma.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
09
2019
revised:
03
03
2020
accepted:
11
03
2020
entrez:
14
4
2020
pubmed:
14
4
2020
medline:
8
1
2021
Statut:
epublish
Résumé
Numerous microRNAs (miRNAs) have been identified in ccRCC and recommended to be used for predicting clear cell renal cell carcinoma (ccRCC) prognosis. However, it is not clear whether a miRNA-based nomogram results in improved survival prediction in patients with ccRCC. miRNA profiles from tumors and normal tissues were downloaded from The Cancer Genome Atlas (TCGA) database and analyzed using the "limma" package. The association between differentially expressed miRNAs and patient prognosis was identified using univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses. Next, all patients were randomly divided into development and validation cohorts at a ratio of 1 : 1. A nomogram was established based on independent prognostic factors in the development cohort. The prognostic performance of the nomogram was validated in both cohorts using the concordance index (C-index) and calibration plots. Multivariate Cox analysis identified the 13-miRNA signature, as well as AJCC stage and age, as independent prognostic factors after adjusting for other clinical covariates. The nomogram was built based on the independent variables. In the development cohort, the C-index for the constructed nomogram to predict overall survival (OS) was 0.792, which was higher than the C-index (0.731) of the AJCC staging system and C-index (0.778) of the miRNA signature. The nomogram demonstrated good discriminative ability in the validation cohort in predicting OS, with a C-index of 0.762. The calibration plots indicated an excellent agreement between the nomogram predicted survival probability and the actual observed outcomes. Furthermore, decision curve analysis (DCA) indicated that the nomogram was superior to the AJCC staging system in increasing the net clinical benefit. The novel proposed nomogram based on a miRNA signature is a more reliable and robust tool for predicting the OS of patients with ccRCC compared to AJCC staging system, thus, improving clinical decision-making.
Identifiants
pubmed: 32280701
doi: 10.1155/2020/7434737
pmc: PMC7128070
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7434737Informations de copyright
Copyright © 2020 Enfa Zhao and Xiaofang Bai.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Urology. 2010 Dec;76(6):1298-301
pubmed: 21030068
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
J Cancer Res Clin Oncol. 2014 Aug;140(8):1295-304
pubmed: 24802708
PLoS One. 2017 Jun 29;12(6):e0180660
pubmed: 28662155
Cancer Treat Rev. 2016 Nov;50:109-117
pubmed: 27664394
Onco Targets Ther. 2016 Apr 12;9:2131-41
pubmed: 27110129
Cancer Manag Res. 2018 Nov 15;10:5759-5766
pubmed: 30532596
Eur Urol. 2004 Nov;46(5):559-64
pubmed: 15474263
J Urol. 2008 Jul;180(1):72-8
pubmed: 18485380
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
Mol Oncol. 2012 Dec;6(6):590-610
pubmed: 23102669
Epidemiology. 2009 Jul;20(4):555-61
pubmed: 19367167
Liver Int. 2020 Jan;40(1):205-214
pubmed: 31505104
J Thorac Dis. 2019 Jul;11(7):2868-2877
pubmed: 31463116
Eur Radiol. 2020 Feb;30(2):1274-1284
pubmed: 31506816
Cell. 2013 Apr 25;153(3):516-9
pubmed: 23622238
Eur Urol. 2006 May;49(5):798-805
pubmed: 16442207
Semin Cancer Biol. 2013 Feb;23(1):10-7
pubmed: 22750267
J Clin Oncol. 2015 Mar 10;33(8):861-9
pubmed: 25624438
Genome Biol. 2010;11(10):R106
pubmed: 20979621
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
J Cell Biochem. 2019 Aug;120(8):13751-13764
pubmed: 30957284
J Clin Oncol. 2014 Jun 20;32(18):1968-76
pubmed: 24821879
Cancer. 2004 Jan 1;100(1):1-5
pubmed: 14692017
Lancet Oncol. 2007 Jun;8(6):554-8
pubmed: 17540307
Radiother Oncol. 2019 Mar;132:34-41
pubmed: 30825967
Cancer Metastasis Rev. 2015 Mar;34(1):145-55
pubmed: 25721950
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
J Kidney Cancer VHL. 2015 Aug 23;2(4):140-152
pubmed: 28326269
Eur Urol. 2011 Oct;60(4):644-61
pubmed: 21741163
Eur Urol. 2016 Aug;70(2):312-22
pubmed: 26806656
Int J Surg. 2018 Dec;60:28-40
pubmed: 30389534
Eur Radiol. 2020 Feb;30(2):976-986
pubmed: 31468157